Neumora Therapeutics (NASDAQ:NMRA) Releases Earnings Results, Misses Expectations By $0.01 EPS

Neumora Therapeutics (NASDAQ:NMRA) issued its quarterly earnings results on Monday. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01), FiscalAI reports.

Here are the key takeaways from Neumora Therapeutics’ conference call:

• NMRA-511 showed a clinically meaningful effect in a pre-specified Phase 1b subgroup (NPI‑AA ≥4) with a Cohen’s d of ~0.32–0.34 on CMAI and a favorable tolerability profile (no somnolence), and a MAD extension (higher doses) will report in H2 2026 ahead of a planned Phase II in Q1 2027.
• The Phase III navacaprant KOASTAL‑2 and KOASTAL‑3 trials are fully enrolled (>400 patients each) with a joint top-line readout expected in Q2 2026; the company implemented screening/site optimizations and believes one positive study plus supportive evidence could permit a pre‑NDA discussion with the FDA.
• While NMRA‑215 delivered class-leading 12‑week DIO mouse data (monotherapy, combination, and weight‑loss maintenance), unexpected non‑dose‑dependent adverse findings in a small number of rats in a 13‑week tox study triggered a for‑cause audit and a repeat 13‑week rat study, delaying clinical entry to Q1 2027.
• The company designated NMRA‑898 as its lead M4 PAM for schizophrenia after Phase I signals—~80–100 hour half‑life supporting once‑daily dosing, dose‑proportional exposure, CNS penetration above in vitro EC50 and PD heart‑rate effects—and MAD data are expected in H2 2026.
• Neumora ended 2025 with $182.5 million in cash and marketable securities, which management says funds operations into Q3 2027, providing runway for upcoming catalysts but implying potential need for additional financing thereafter.

Neumora Therapeutics Stock Performance

Shares of NASDAQ NMRA opened at $1.95 on Wednesday. The stock has a 50 day moving average price of $2.74 and a 200 day moving average price of $2.32. Neumora Therapeutics has a 52 week low of $0.61 and a 52 week high of $3.65. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85. The stock has a market capitalization of $325.83 million, a PE ratio of -1.34 and a beta of 2.49.

Neumora Therapeutics News Summary

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: Major firms reaffirmed buy ratings with large price targets—Guggenheim set a $14 target (very large upside) which boosts investor optimism about long‑term value. Guggenheim Reaffirms Buy, $14 PT
• Positive Sentiment: Needham also reaffirmed a buy rating and set an $8 price target, reinforcing analyst backing for NMRA’s pipeline recovery potential. Needham Reaffirms Buy, $8 PT
• Positive Sentiment: Company press release and earnings-call highlights emphasize a strong balance sheet and positive early NMRA‑511 data (claimed effect comparable to marketed agents in a prespecified population), which supports upside if later trials confirm signals. Q4 Results & NMRA-511 Data Release
• Neutral Sentiment: Unusually large options buying (roughly 2,812 calls vs. a daily average ~687) and elevated share volume indicate speculative/levered interest that can amplify moves in either direction.
• Negative Sentiment: The company disclosed a Nasdaq delisting risk that could impair liquidity, shareholder value and future capital access—this raises a material tail‑risk for investors. Nasdaq Delisting Risk Disclosure
• Negative Sentiment: Analyst downgrades and caution followed the KOASTAL‑1 failure (navacaprant) in MDD—this clinical setback and the uncertainty around upcoming KOASTAL‑2/3 readouts weigh on near‑term sentiment. SeekAlpha: Downgrade After Navacaprant Setback
• Negative Sentiment: Q4 EPS missed consensus by $0.01 (reported -$0.35 vs. -$0.34), a small miss but relevant given the company is not yet profitable; adds short‑term pressure on valuation. Earnings Release / Transcript

Insider Buying and Selling at Neumora Therapeutics

In other Neumora Therapeutics news, insider Paul L. Berns sold 9,819 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total transaction of $34,464.69. Following the transaction, the insider owned 7,395,185 shares of the company’s stock, valued at $25,957,099.35. The trade was a 0.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 23,387 shares of company stock worth $82,647. 26.80% of the stock is owned by insiders.

Institutional Trading of Neumora Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hsbc Holdings PLC acquired a new stake in Neumora Therapeutics in the fourth quarter valued at $27,000. Virtu Financial LLC bought a new stake in shares of Neumora Therapeutics in the 3rd quarter valued at about $31,000. Fred Alger Management LLC bought a new stake in shares of Neumora Therapeutics in the 4th quarter valued at about $40,000. Canada Pension Plan Investment Board acquired a new stake in Neumora Therapeutics in the 2nd quarter valued at about $41,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in Neumora Therapeutics in the 3rd quarter valued at about $44,000. 47.65% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NMRA has been the topic of a number of recent research reports. Mizuho set a $6.00 target price on Neumora Therapeutics in a research report on Monday, January 5th. Leerink Partners assumed coverage on shares of Neumora Therapeutics in a research note on Monday, January 12th. They set an “outperform” rating and a $8.00 price target for the company. Guggenheim reiterated a “buy” rating and issued a $14.00 price objective on shares of Neumora Therapeutics in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Thursday, January 22nd. Finally, Needham & Company LLC restated a “buy” rating and set a $8.00 target price on shares of Neumora Therapeutics in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $6.71.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.